At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of CLL, small lymphocytic lymphoma, CLL progressing to prolymphocytic leukemia, T-cell CLL, or PLL
- ✓For B-Cell CLL/PLL: failed to meet NCI response criteria after fludarabine-based therapy OR disease relapse within 12 months of completing fludarabine-based therapy
- ✓Failed FCR combination chemotherapy at any point
- ✓De novo or acquired 17p deletion cytogenetic abnormality (may be transplanted in first complete response if induction chemotherapy received)
- ✕HIV, HTLV-1, or HTLV-2 infection
- ✕Active CNS involvement with CLL
- ✕Active non-hematologic malignancies (except non-melanoma skin cancers)
- ✕History of non-hematologic malignancies (except non-melanoma skin cancers) not in complete remission for ≥5 years with >20% recurrence risk
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial
In Brief
A Phase 2 clinical trial evaluating Cyclosporine, Fludarabine Phosphate, and 5 other interventions for B-Cell Prolymphocytic Leukemia and 6 related conditions. Completed, enrolled 21 participants across 3 sites in 2 countries.
Detailed Summary
This clinical trial studies how well giving fludarabine phosphate together with total-body irradiation (TBI) before donor peripheral blood stem cell transplant works in treating patients with chronic lymphocytic leukemia or small lymphocytic leukemia. Giving low doses of chemotherapy, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. Giving chemotherapy before or after peripheral blood stem cell transplant also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after the transplant may stop this from happening.
Study Details
Timeline
Interventions
Given PO
Given IV
Undergo allogeneic peripheral blood stem cell transplant
Correlative studies
Given PO
Undergo allogeneic peripheral blood stem cell transplant
Undergo TBI